Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Authors
  • Kabbinavar, Fairooz F
  • Hurwitz, Herbert I
  • Yi, Jing
  • Sarkar, Somnath
  • Rosen, Oliver
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Jan 10, 2009
Volume
27
Issue
2
Pages
199–205
Identifiers
DOI: 10.1200/JCO.2008.17.7931
PMID: 19064978
Source
Medline
License
Unknown

Abstract

Analysis of pooled patient cohorts age >/= 65 years from two similar trials in mCRC indicates that adding bevacizumab to fluorouracil-based chemotherapy improved OS and PFS, similar to the benefits in younger patients. Also, the risks of treatment do not seem to exceed those in younger patients with mCRC.

Report this publication

Statistics

Seen <100 times